Nivolumab plus ipilimumab in malignant pleural mesothelioma
Nivolumab plus ipilimumab in malignant pleural mesothelioma
复制标题
纳武单抗联合伊匹单抗治疗恶性胸膜间皮瘤
DOI：
--
复制
发表时间：
2022
影响因子：
3.3
通讯作者：
L. Greillier
中科院分区：
文献类型：
--
作者：
Camille Travert;P. Tomasini;L. Greillier
摘要引言不可切除的胸膜间皮瘤是一种预后不良的疾病。培美曲塞联合顺铂可改善总生存期（OS）。与单独化疗相比，贝伐珠单抗联合化疗可改善OS，但并不受各地医疗保险的支持。免疫检查点抑制（ICI）单药治疗所涵盖的领域似乎很有前途，但存在争议。ICI联合用药效果显著。在最近发表的两项II期试验和一项III期试验中，对NIVOLUMAB（一种抗程序性死亡受体1）与IPILIMUMAB（一种抗细胞毒性T淋巴细胞相关蛋白4）联合使用进行了评价。与化疗相比，这种联合治疗使一线患者的生存期显著获益（OS 18.1个月（95%CI（16.8-21.4））vs 14.1个月（95%CI（12.4-16.2）HR 0.74（95%CI 0.6-0.91）p = 0.002）。专家观点这些结果代表了不可切除的胸膜间皮瘤的一大步。在非上皮样亚型中的获益令人印象深刻（OS 18.1个月（95%CI 12.2-22.8）vs 8.8个月（95%CI（7.4-10.2）HR 0.46（95%CI（0.31-0.68）。上皮样亚型的获益（OS 18.7个月95%CI（16.9-22）vs 16.5 95%CI（14.9-20.5）HR 0.86 95%CI（0.69-1.08））与贝伐珠单抗联合化疗的获益相似。需要鉴定预测性生物标志物以鉴定最有可能从每种治疗策略中获益的患者。
ABSTRACT Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN. BEVACIZUMAB combined with chemotherapy is associated with an improvement in OS, compared to chemotherapy alone, but is not supported by health insurance everywhere. Areas covered Immune Checkpoint Inhibition (ICI) monotherapy seemed to be promising but is controversial. ICI combination showed significant results. NIVOLUMAB, an anti-Programmed-Death-receptor 1, associated with IPILIMUMAB, an anti-Cytotoxic-T-Lymphocyte-Associated-protein 4, was evaluated in two phase II trials and a phase III trial, recently published. This combination led to a significant benefit in survival in first line compared to chemotherapy (OS 18.1 months (95%CI (16.8–21.4)) vs 14.1 (95%CI (12.4–16.2) HR 0.74 (95%CI 0.6–0.91) p = 0.002). Expert opinion These results represent a big step in unresectable pleural mesothelioma. The benefit in non-epithelioid subtype is impressive (OS 18.1 months (95%CI 12.2–22.8) vs 8.8 months 95%CI (7.4–10.2) HR 0.46 (95%CI (0.31–0.68))). Benefit in epithelioid subtype (OS 18.7 months 95%CI (16.9–22) vs 16.5 95%CI (14.9–20.5) HR 0.86 95%CI (0.69–1.08)) is similar to the benefit of the combination of BEVACIZUMAB and chemotherapy. Identification of predictive biomarkers is needed to identify patients who are most likely to benefit from each therapeutic strategy.
登录
查看更多内容
DOI：
10.1200/jco.2009.26.7609
发表时间：
2010-07-01
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Brahmer JR;Drake CG;Wollner I;Powderly JD;Picus J;Sharfman WH;Stankevich E;Pons A;Salay TM;McMiller TL;Gilson MM;Wang C;Selby M;Taube JM;Anders R;Chen L;Korman AJ;Pardoll DM;Lowy I;Topalian SL
通讯作者：
Topalian SL
DOI：
10.6004/jnccn.2016.0087
发表时间：
2016-07
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
Ettinger DS;Wood DE;Akerley W;Bazhenova LA;Borghaei H;Camidge DR;Cheney RT;Chirieac LR;D'Amico TA;Dilling T;Dobelbower M;Govindan R;Hennon M;Horn L;Jahan TM;Komaki R;Lackner RP;Lanuti M;Lilenbaum R;Lin J;Loo BW Jr;Martins R;Otterson GA;Patel JD;Pisters KM;Reckamp K;Riely GJ;Schild SE;Shapiro TA;Sharma N;Swanson SJ;Stevenson J;Tauer K;Yang SC;Gregory K;Hughes M
通讯作者：
Hughes M
DOI：
--
发表时间：
2019
期刊：
--
影响因子：
--
作者：
Doreen Agnese;Kimberly H. Allison;Sarah L. Blair;H. Burstein;Anthony D. Elias;Sharon H. Giordano
通讯作者：
Doreen Agnese;Kimberly H. Allison;Sarah L. Blair;H. Burstein;Anthony D. Elias;Sharon H. Giordano
DOI：
10.1056/nejmoa1200690
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Topalian SL;Hodi FS;Brahmer JR;Gettinger SN;Smith DC;McDermott DF;Powderly JD;Carvajal RD;Sosman JA;Atkins MB;Leming PD;Spigel DR;Antonia SJ;Horn L;Drake CG;Pardoll DM;Chen L;Sharfman WH;Anders RA;Taube JM;McMiller TL;Xu H;Korman AJ;Jure-Kunkel M;Agrawal S;McDonald D;Kollia GD;Gupta A;Wigginton JM;Sznol M
通讯作者：
Sznol M